1、 Product introduction
Chinese Name | English Name | Declaration Type | Department | Reportable Dosage Form | Declaration Progress | Strength | CAS |
| 富马酸替诺福韦二吡呋酯 | Tenofovir disoproxil fumarate | 5+4 | antiviral | Tablet / powder / capsule | Ready to declare | Tablet：150mg、200mg、250mg、300mg， Powder：40mg， Capsule ：300mg | 202138-50-9 |
【Indication】
Treatment of HIV infection.
【Reportable Dosage Form &Strength】
Tablet： 150mg、200mg、250mg、300mg，
Powder：40mg，
Capsule ：300mg
【Mechanism of Action】
Novel nucleotide reverse transcriptase inhibitors.
【Development Progress】
About to be accepted
2、 Clinical Advantages
Tenofovir is a first-line antiviral drug recommended by who AIDS treatment guidelines. In China, it is listed as the first-line drug of free AIDS antiviral treatment.
3、Domestic Declaration
Declaration Type | Reportable Dosage Form | Number of Declared Preparations | Number of Existing Preparation Enterprises |
| 5+4 | Tablet | Tablet ：20 domestic powder ：3 domestic capsule：3 domestic Compound：1 imported
| Tablet ：1 imported |
![Brinzolamide 布林佐胺 CAS号：138890-62-7]( "Brinzolamide 布林佐胺 CAS号：138890-62-7")
Guangzhou Tosun Pharmaceutical Ltd
FL 4-5,No.3, 2nd Kehui street, Science Park, Guangzhou High-tech Industrial Development Zone, Guangzhou, China. 510663
Tel: +86-20-66392521； Fax: +86-20-66392525